New Licence Extension For Vetmedin Is EPIC!
7 years ago 
2092 views
Following the largest and most cutting-edge study in veterinary cardiology, Boehringer Ingelheim has extended the licence for Vetmedin. This new claim will revolutionise the treatment of dogs with asymptomatic mitral valve disease (MVD)*.
The EPIC study (Effect of Pimobendan in Dogs with asymptomatic MVD and Cardiomegaly)1 demonstrated that Vetmedin delayed the onset of heart failure for dogs with asymptomatic MVD, providing on average 15 months additional symptom-free time, as well as extending overall survival. Indeed, this worldwide study was so conclusive - involving 360 dogs, in 36 centres, in 11 countries across four continents - that it was terminated early as it was deemed unethical to withhold Vetmedin from dogs in the placebo group.
Vetmedin is the only medication licensed to treat asymptomatic MVD in dogs. Vetmedin will have a major impact on the longevity and quality of life of affected dogs by delaying the onset of heart failure and providing them with more symptom-free time with their owners.
Panny Morgan, Vetmedin brand manager at Boehringer Ingelheim, comments: “Vetmedin delays the onset of heart failure in dogs with asymptomatic MVD and cardiomegaly, providing 15 months extra symptom-free time; that’s almost 10% of a dog’s lifetime. Prescribing Vetmedin to dogs with an MVD murmur and enlarged heart will not only extend a dog’s lifespan, but it will also have a major impact on their quality of life.”
For further information on Vetmedin, please contact your Boehringer Ingelheim territory manager or visit www.vetmedin.co.uk.
* and cardiomegaly
Reference
1 Boswood et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial. J Vet Intern Med 2016;30:1765–1779
More from Boehringer Ingelheim
- Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
- Boehringer Ingelheim Animal Health launches new ProZinc webinar and toolkit
- NexGard Spectra ‘Yum and Done’ competition winner announced
- Boehringer Ingelheim launches Parassess - a “first-of-its-kind”, online, personalised dog parasite risk checker
- ABCD & Boehringer Ingelheim invite applications for the 2022 Young Scientist Award
